Portal de Periódicos da CAPES

Soluble lnterleukin-2 Receptor in Sera of Patients with Pulmonary Tuberculosis

1991; Elsevier BV; Volume: 99; Issue: 2 Linguagem: Inglês

10.1378/chest.99.2.310

1931-3543

Satsuki Takahashi, Yasuhiro Setoguchi, Toshihiro Nukiwa, Shiro Kira,

Galectins and Cancer Biology

Interleukin-2 receptor, the complex of LL-2R-α and/or EL-2R-β, is expressed mainly on T-lymphocytes, and the soluble form of EL-2R-α (sIL-2R-α) has been reported to be detected in the serum of patients with lymphoproliferative disorders or diseases characterized by the cellular immune reaction. We measured serum sIL-2R-α levels among patients with pulmonary diseases and found that sIL-2R-α levels were significantly elevated in patients with active pulmonary tuberculosis (1,327 ± 209 U/ml) and sarcoidosis (1,037 ± 115 U/ml) when compared with healthy volunteers (468 ± 49 U/ml, p<0.01). Among patients with pulmonary tuberculosis, the sIL-2R-α levels were high in sera from patients with extensive parenchymal lesions on the roentgenogram (2,745 ± 705 U/ml) and patients with tuberculous pleurisy (2,111 ± 679 U/ml). In contrast, the sIL-2R-α levels in tuberculous patients with minimal lesion (455 ± 92 U/ml) or moderate lesion (1,082 ± 189 U/ml) were not significantly elevated when compared with healthy volunteers. After the treatment with antituberculosis agents, serum sIL-2R-α levels decreased in accordance with improvement of roentgenographic findings and laboratory data. These results suggest that serum sIL-2R-α level may be useful as a monitor for the disease activity in patients with pulmonary tuberculosis. Interleukin-2 receptor, the complex of LL-2R-α and/or EL-2R-β, is expressed mainly on T-lymphocytes, and the soluble form of EL-2R-α (sIL-2R-α) has been reported to be detected in the serum of patients with lymphoproliferative disorders or diseases characterized by the cellular immune reaction. We measured serum sIL-2R-α levels among patients with pulmonary diseases and found that sIL-2R-α levels were significantly elevated in patients with active pulmonary tuberculosis (1,327 ± 209 U/ml) and sarcoidosis (1,037 ± 115 U/ml) when compared with healthy volunteers (468 ± 49 U/ml, p<0.01). Among patients with pulmonary tuberculosis, the sIL-2R-α levels were high in sera from patients with extensive parenchymal lesions on the roentgenogram (2,745 ± 705 U/ml) and patients with tuberculous pleurisy (2,111 ± 679 U/ml). In contrast, the sIL-2R-α levels in tuberculous patients with minimal lesion (455 ± 92 U/ml) or moderate lesion (1,082 ± 189 U/ml) were not significantly elevated when compared with healthy volunteers. After the treatment with antituberculosis agents, serum sIL-2R-α levels decreased in accordance with improvement of roentgenographic findings and laboratory data. These results suggest that serum sIL-2R-α level may be useful as a monitor for the disease activity in patients with pulmonary tuberculosis. Clinical Applications of Soluble lnterleukin-2 Receptor in Granulomatous DiseaseCHESTVol. 99Issue 2PreviewIn this issue of Chest (see page 310 ) Takahashi and colleagues measured soluble interleukin-2 receptors in patients with lung disease and in healthy volunteers. They found higher levels in those with tuberculosis and sarcoidosis. The serum levels correlated with disease activity. This follows reports of increased soluble interleukin-2 receptors in serum and bronchoalveolar lavage fluid in patients with sarcoidosis,1,2 and is one of several recent articles that indicate how knowledge of T-cell proteins and their receptors may be applied clinically in the future. Full-Text PDF